Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death in China and, thus, a major public health concern. We expect the Chinese COPD therapy market to experience robust growth over the 2020-2030 forecast period, driven by the uptake of several recently launched, novel, premium-priced therapies—including LAMA/LABA FDCs and ICS/LAMA/LABA FDCs—and their inclusion in China’s National Reimbursement Drug List. Given the diverse late-phase pipeline, we expect more novel therapies to launch during the forecast period, further driving market growth. Additionally, in view of the ongoing reforms in China’s regulatory and access and reimbursement landscape, multinational companies will be encouraged to enter this market.
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 pulmonologists.
Diagnosed prevalence of COPD in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations
10-year, annualized, drug-level sales and patient share of key COPD therapies through 2030, based on primary and secondary market research to formulate bottom-up assumptions
Phase III/PR: 9 drugs; Phase II: 3 drugs; coverage of select preclinical and Phase I products.